Recruiting PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT06379113

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole in Obese Progestin-insensitive Early-stage Endometrial Cancer Patients With Conservative Treatment

Sponsor: Xiaojun Chen

Conditions Atypical Endometrial Hyperplasia Endometrial Neoplasms Obesity Progesterone Resistance

Interventions GnRH antagonist Letrozole 2.5mg

Updated 5 times since 2024 Last updated: Aug 6, 2025 Started: Jul 13, 2022 Primary completion: Mar 30, 2026 Completion: Mar 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Atypical Endometrial Hyperplasia and Endometrial Neoplasms and is currently actively recruiting participants. Xiaojun Chen leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Recruiting PHASE2/PHASE3
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2/PHASE3
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
May 2024 — Jul 2024 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Jul 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Xiaojun Chen

Data source: Fudan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China